D. Lawrence Wickerham, MD,1,17 Norman Wolmark, MD1,17

Slides:



Advertisements
Similar presentations
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Advertisements

Robertson JFR et al. J Clin Oncol 2009;27(27):
INIBITORI DELL’AROMATASI
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Study Of Letrozole Extension
Description of fracture with endocrine therapy use in older breast cancer survivors in a population-based setting Taryn Becker 123, Geoff Anderson 123,
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
Clinicaloptions.com/oncology FRANCESCO BOCCARDO Professore Ordinario di Oncologia Medica, Università di Genova Direttore Oncologia Medica B IST.Genova.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
These slides were released by the speaker for internal use by Novartis
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Start or Switch?: Latest data from ABCSG/ARNO
DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
Anastrozole (‘Arimidex’): a new standard of care?
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast.
High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial 1 San Antonio.
San Antonio Breast Cancer Symposium, December 8-12, 2015
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.
CCO Independent Conference Coverage
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
San Antonio Breast Cancer Symposium – December 6-10, 2016
CCO Independent Conference Highlights
San Antonio Breast Cancer Symposium, December 6-10, 2016
Zoneddy Dayao, Rachel Rabinovitch, Stephen H. Dyar,
Slamon D et al. SABCS 2009;Abstract 62.
B-31/N9831 First Interim Joint Analysis
Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
San Antonio Breast Cancer Symposium. December
Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*
Adjuvant Hormonal Therapy for Premenopausal Women
Prognostic significance of tumor subtypes in male breast cancer:
EXTENDED ENDOCRINE TREATMENT IN BREAST CANCER
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis  Peyman Hadji  Critical Reviews in Oncology.
JOURNAL OF CLINICAL ONCOLOGY 25:
Mostafa AL Turk Tatiana Hawat
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
Figure 2. A consort diagram showing the flowchart of the trial
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
CCO Independent Conference Coverage
San Antonio Breast Cancer Symposium, December 5-9, 2017
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Early Breast Cancer Clinical Trialists’ Collaborative Group
San Antonio Breast Cancer Symposium, December 6-10, 2016
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Untch M et al. Proc SABCS 2010;Abstract P
The Research Question RESEARCH METHOD
Effect of Obesity on Prognosis after Early Breast Cancer
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
Martin M et al. Proc SABCS 2012;Abstract S1-7.
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Authors: Sunil Verma Date posted: December 22, 2008
Presentation transcript:

D. Lawrence Wickerham, MD,1,17 Norman Wolmark, MD1,17 San Antonio Breast Cancer Symposium - December 6-10, 2016 A Randomized, Double-blinded, Placebo-controlled Clinical Trial of Extended Adjuvant Endocrine Therapy with Letrozole in Postmenopausal Women with Hormone-receptor (+) Breast Cancer who have Completed Previous Adjuvant Tx with an Aromatase Inhibitor: Results from NRG Oncology/NSABP B-42 Eleftherios P. Mamounas, MD,1,2 Hanna Bandos, PhD1,3 Barry C. Lembersky, MD,1,4 Charles E. Geyer, Jr., MD,1,5 Louis Fehrenbacher, MD,1,6 Mark L. Graham, MD,1,7 Stephen L. Chia, MD, FRCPC1,8 Adam M. Brufsky, MD, PhD,1,4 Bryan T. Hennessy, MD,1,9 Gamini S. Soori, MD,1,10 Shaker R. Dakhil, MD,1,11 Thomas E. Seay, MD,1,12 James L. Wade, III, MD,1,13 Edward C. McCarron, MD,1,14 Soonmyung Paik, MD,1,15 Sandra M. Swain, MD,1,16 D. Lawrence Wickerham, MD,1,17 Norman Wolmark, MD1,17 1NRG Oncology/NSABP (NSABP Legacy trials are now part of the NRG Oncology portfolio), Pittsburgh, PA; 2UF Cancer Center at Orlando Health, Orlando, FL; 3University of Pittsburgh, Pittsburgh, PA; 4University of Pittsburgh Cancer Institute, Pittsburgh, PA; 5Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; 6Kaiser Permanente Oncology Clinical Trials Norther California, Vallejo, CA; 7Southeast Cancer Control Consortium, Goldsboro, NC; 8British Columbia Cancer Agency (BCCA),Vancouver, British Columbia, Canada; 9Cancer Trials Ireland (Formerly known as Irish Clinical Oncology Research Group - ICORG), Dublin, Ireland; 10Missouri Valley Cancer Consortium, Omaha, NE; 11CCOP, Wichita Cancer Center of Kansas, Wichita, KS; 12Georgia NCI Community Oncology Research Program, Atlanta, GA; 13CCOP, Central Illinois, Decatur, IL; 14MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, MD; 15Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea; 16Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC; 17Allegheny Health Network Cancer Institute, Pittsburgh, PA This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Background/Rationale San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Background/Rationale Extended adjuvant endocrine therapy after 5 years of tamoxifen with either an aromatase inhibitor or tamoxifen improves disease-free survival in early-stage breast cancer Optimal duration of adjuvant aromatase inhibitor therapy beyond 5 years is unknown NSABP B-42 aimed to determine whether 5 years of letrozole vs. placebo improves disease-free survival in patients who have completed 5 years of hormonal therapy with either an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

R NSABP B-42: Schema or Stratification: San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Schema Postmenopausal Pts with ER+ or PR+ Breast Cancer Stage I, II, or IIIa invasive BC at diagnosis Disease-free After 5 Years of Endocrine Therapy or AI X 5 yrs TAM X < 3 yrs  AI to Complete 5 yrs Stratification: Pathological nodal status (Negative, Positive) Prior adjuvant TAM (Yes, No) Lowest BMD T score: spine, hip, femur (>-2.0, ≤ -2.0 SD) R Letrozole X 5 yrs Placebo X 5 yrs This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute.

San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Endpoints Primary endpoint: Disease-free Survival (DFS): Local, regional, distant recurrence, opposite BC, 2nd non-breast primary cancer, and death from any cause as first event Secondary endpoints: Overall survival Breast Cancer-Free Interval (BCFI): Recurrence or opposite BC as first event Distant Recurrence (DR) Osteoporotic fractures (OF) Arterial thrombotic events (AT) This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Patient Population San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Patient Population From September 2006 to January 2010, 3966 pts were randomized 43 patients excluded: 36 no follow-up; 7 not at risk for the primary endpoint Median follow-up for 3923 pts included in efficacy analyses was 6.9 years The required 631 DFS events for definitive analysis occurred by August 2016 This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Patient Characteristics San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Patient Characteristics No significant differences in the distribution of patient, tumor, and prior treatment characteristics between the two treatment groups: 34-35% <60 years of age 57-58% node-negative 39% received prior tamoxifen 61% breast-conserving surgery This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Treatment Compliance San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Treatment Compliance Median duration of treatment was 59.8 months in both groups Overall, 62.5% of placebo patients and 60.3% of letrozole patients completed 5 years of therapy Main reasons for letrozole treatment discontinuation: Patient withdrawal/refusal: 13.8% Adverse Event: 9.6% Disease Progression: 4.1% This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

San Antonio Breast Cancer Symposium - December 6-10, 2016 Results This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Disease-Free Survival San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Disease-Free Survival Letrozole Placebo 100 80 60 40 20 0 2 4 6 7 8 Years After Randomization Disease-Free Survival Letrozole 1959 1813 1644 1225 216 Placebo 1964 1814 1639 1208 210 HR=0.85 (0.73-0.999) P = 0.048 84.7% 81.3% # Events 292 339 *P-value did not reach statistical significance level of 0.0418 This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: DFS First Events by Treatment San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: DFS First Events by Treatment   Placebo (n=1964) Letrozole (n=1959) First event # % Distant Recurrence 87 4.4 61 3.1 Local Recurrence 33 1.7 36 1.8 Second Primary Ca 171 8.7 134 6.8 Opposite Breast 59 3.0 30 1.5 Non-Breast 112 5.7 104 5.3 Death 48 2.4 Total First Event 339 17.3 292 14.9 This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Cumulative Incidence of BCFI Event San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Cumulative Incidence of BCFI Event Letrozole Placebo Cumulative Incidence of BCFI Event 12 10 8 6 4 2 0 2 4 6 7 8 Years After Randomization 10.0% 6.7% HR=0.71 (0.56-0.89) P=0.003 # Pts # Events 1959 127 1964 179 This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Cumulative Incidence of Distant Recurrence San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Cumulative Incidence of Distant Recurrence Letrozole Placebo Cumulative Incidence of DR 12 10 8 6 4 2 0 2 4 6 7 8 5.8% 3.9% HR=0.72 (0.53-0.97) P=0.03 Years After Randomization # Pts # Events 73 1964 102 This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Overall Survival San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Overall Survival Letrozole Placebo 100 80 60 40 20 0 2 4 6 8 Years After Randomization Disease-Free Survival 0 2 4 6 7 8 Letrozole 1959 1902 1781 1499 287 Placebo 1964 1902 1791 1528 291 Overall Survival 92.3% 91.8% HR=1.15 (0.99-1.44) P=0.22 # Deaths 164 146 This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Cumulative Incidence of Osteoporotic Fx San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Cumulative Incidence of Osteoporotic Fx Letrozole Placebo Cumulative Incidence of Osteoporotic Fx 12 10 8 6 4 2 0 2 4 6 7 8 5.4% HR=1.19 (0.88-1.60) P=0.27 Years After Randomization 4.8 % # Events 91 78 This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Cum. Inc. of Arterial Thrombotic Events San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Cum. Inc. of Arterial Thrombotic Events 12 10 8 6 4 2 # Events 71 59 Letrozole Placebo HR=1.21 (0.85-1.70) P=0.29 Cum. Inc. of Arterial Thrombotic Events 4.0% 3.4 % 0 2 4 6 7 8 Years After Randomization This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Summary The beneficial effect of extended letrozole therapy on DFS did not reach statistical significance (15% reduction) No significant difference in overall survival Extended letrozole provided: Statistically significant improvement in BCFI (29% reduction in BCFI event) Statistically significant reduction in the rate of DR (28% reduction in DR) Letrozole did not significantly increase risk of osteoporotic fractures but risk of arterial thrombotic events was elevated for letrozole after 2.5 years This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

NSABP B-42: Conclusions and Perspective San Antonio Breast Cancer Symposium - December 6-10, 2016 NSABP B-42: Conclusions and Perspective Our findings suggest that careful assessment of potential risks and benefits is required before recommending extended letrozole therapy in patients with early-stage BC, including: Patient and tumor characteristics (age, nodal status) Existing co-morbidities Information on bone mineral density Tolerance of the AI in the initial 5 years Genomic classifiers that predict risk of late recurrence and/or benefit from extended endocrine therapy may help to further individualize the recommendation for extended aromatase inhibitor therapy This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute

San Antonio Breast Cancer Symposium - December 6-10, 2016 Acknowledgements The 3,966 patients who participated in the trial The NSABP Investigators/Coordinators Hanna Bandos and Barry Lembersky The NSABP Operations and Biostatistics Center staff NCI CTEP and Novartis This presentation is the intellectual property of the author/presenter. Contact them at terry.mamounas@orlandohealth.com for permission to reprint and/or distribute